Equillium Inc

NASDAQ:EQ  
5.94
+0.08 (+1.36%)
Products, Regulatory

Equillium Announces Favorable Data From Phase 1B Equalise Study In Systemic Lupus Erythematosus Patients

Published: 03/30/2021 20:41 GMT
Equillium Inc (EQ) - Equillium Announces Favorable Data From Phase 1b Equalise Study in Systemic Lupus Erythematosus Patients.
Equillium Inc - Itolizumab Administered Subcutaneously Was Safe and Well Tolerated in Patients With Systemic Lupus Erythematosus.
Equillium - Dose-dependent Changes in Pharmacodynamic Markers Observed With Subcutaneous Dosing Were Consistent With Intravenous Dosing of Itolizumab.